Genetic Technologies Interview Aired on Bloomberg International on the RedChip Money Report
November 23 2020 - 4:30PM
Molecular diagnostics company Genetic Technologies Limited (ASX:
GTG; Nasdaq: GENE, “Company”) is pleased to announce an
interview with its interim-CEO, Dr. Jerzy Muchnicki aired on The
RedChip Money Report television program. The RedChip Money Report
airs in 100 million homes on Sundays at 6 p.m. local time in every
country in Europe on Bloomberg International.
In the exclusive interview, Dr. Muchnicki discusses
the Company’s innovative disease risk assessment tests for
COVID-19, cancer, and more.
To view the interview segment, please visit:
https://youtu.be/l3w_9HDvewM
“The RedChip Money Report" delivers insightful
commentary on small cap investing, interviews with Wall Street
analysts, financial book reviews, as well as featured interviews
with executives of public companies.
About Genetic Technologies
Limited
Genetic Technologies Limited is a diversified
molecular diagnostics company. GTG offers cancer predictive testing
and assessment tools to help physicians proactively manage patient
health. The Company's lead products GeneType for Breast Cancer for
non-hereditary breast cancer and GeneType for Colorectal Cancer are
clinically validated risk assessment tests and are first in class.
Genetic Technologies is developing a pipeline of risk assessment
products.
For more information, please
visit www.gtglabs.com
Cautionary Note Regarding Forward-Looking
Statements
Certain statements in this press release constitute
“forward-looking statements,” within the meaning of federal
securities laws, including statements related to the Company’s
anticipated use of proceeds and plans and prospects and other
statements containing the words “anticipate,” “intend,” “may,”
“plan,” “predict,” “will,” “would,” “could,” “should,” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
The Company's actual results could differ materially from those
anticipated in these forward-looking statements as a result of
various factors. Factors that could cause future results to
materially differ from the recent results or those projected in
forward-looking statements include the known risks, uncertainties
and other factors described in the Company’s prior filings and from
time to time in the Company’s subsequent filings with the
Securities and Exchange Commission. Any change in such factors,
risks and uncertainties may cause the actual results, events and
performance to differ materially from those referred to in such
statements. All information in this press release is as of the date
of the release and the Company does not undertake any duty to
update this information, including any forward-looking statements,
unless required by law.
FOR FURTHER INFORMATION PLEASE CONTACT
Investor Relations and Media
(US)Dave Gentry, CEORedChip CompaniesOffice: 1 800 RED
CHIP (733 2447)Cell: US 407 491 4498dave@redchip.com
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Sep 2023 to Sep 2024